Company: LCTX
Filing Date: 2025-04-29
Form Type: DEF 14A
Source: 0000950170-25-060090
Chunk: 17

Company: Lineage Cell Therapeutics, Inc.
Filing Date: 2025-04-29
Form: DEF 14A
Chunk 17
---
 Section 803(B)(2) of the NYSE American Company Guide and Section 10A-3 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and that the members of our Compensation Committee meet the additional independence standards under Section 805(c)(1) of the NYSE American Company Guide. In making its independence determinations, our Board considered (i) the transactions, relationships and arrangements described below under “Certain Relationships and Related Transactions,” (ii) the compensation described above under “Board of Directors - Non-Employee Director Compensation,” (iii) with respect to Mr. Bradsher, his relationship with Broadwood Capital, Inc., our largest shareholder, which beneficially owns more than 20% of our common shares; and (iv) with respect to Ms. Andrews, her appointment in March 2025 as Interim Chief Financial Officer of STAAR Surgical Company, of which Broadwood Capital, Inc. currently owns approximately 22% of its outstanding shares and is its largest shareholder.

Mr. Culley does not qualify as an “independent” director under Section 803(A) of the NYSE American Company Guide because he is our Chief Executive Officer.

<div align='center'>-10-</div>

Board Experience Our Board is currently comprised of people with substantial experience in biotechnology, the pharmaceutical industry, corporate management, finance, and law, and other perspectives that we believe expand our Board’s understanding of the needs and viewpoints of our employees, shareholders, and other stakeholders. Board Committees Our Board has an Audit Committee, a Nominating and Corporate Governance Committee, and a Compensation Committee. The members of each of these committees are independent in accordance with Section 803(A) of the NYSE American Company Guides and Section 10A-3 under the Exchange Act. The members of our Audit Committee and Compensation Committee must also meet the independence tests applicable to members of those committees under the NYSE American Company Guide. Our Board also has a Financial Strategy Committee, the members of which are not required to be independent. From time to time, our Board may establish ad hoc committees to address particular matters. The table below sets forth the composition of the committees of our Board as of April 18, 2025:

|                       |     | Audit  |     | Compensation |     | Nominating  
 & Corporate 
 Governance  |     | Financial 
 Strategy  |
| Dipti Amin            |     |        |     | Member       |     |             |     |           |
|